Hints and tips:
...In a research note on Monday, Cowen argued that a number of the large pharmaceutical groups, led by Eli Lilly, Sanofi-Aventis and Pfizer, would be worth more if they divested separable business units, which...
...Diabetes medications still make up about 17 per cent of Lilly’s $22bn revenues, but in recent years it has lost ground to rivals such as Merck and Sanofi-Aventis....
International Edition